Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CCS Cell Culture Service Signs Strategic License Agreement with CEVEC Pharmaceuticals

Published: Monday, November 05, 2012
Last Updated: Monday, November 05, 2012
Bookmark and Share
Companies announced today the signing of a strategic license agreement. The license will enable CCS to offer its customers transiently transfected CAP-TTM cells for cell based assay and protein production applications.

The transient CAP-TTM protein production technology is based on CAP® cells, an immortalized cell line for stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns.

The collaboration combines CEVEC's proprietary CAP-TTM expression system with CCS' expertise to produce and process bulk quantities of transiently transfected cells for drug discovery research in pharmaceutical companies worldwide.

"CCS Cell Culture Services is a very experienced and trusted partner for the custom supply of cell based assay reagents. We're very pleased that they will add our CAP-T cells to their cell based assay technology portfolio and we're convinced that the cells will contribute significantly to the drug discovery process in the pharma industry " stated Wolfgang Kintzel, CEO at CEVEC.

Oliver Wehmeier, Managing Director of Cell Culture Services said: "We are excited about the potential of CEVEC's CAP-T technology. The cells meet all requirements for a host cell line in terms of robustness, transfection efficacy, expression level, and scalability. We obtained outstanding results from transient transfections of various secreted, intracellular, or membrane bound target proteins in CAP-T cells and we are pretty sure that this expression system will be of great benefit to our customers"


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
Using Stem Cells to Grow a 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Puttng Cells Through Their Paces
An obstacle course for human lung cells could be the answer for better testing the effectiveness of potential new drugs.
Inherited Heart Condition Breakthrough
Using stem cells, scientists have created a specific heart condition model, yeilding insights into unexpected disease mechanisms.
Genetic Tug of War Before Cells Decide Fate
Researchers report that as developing blood cells are triggered by genetic signals firing on and off, a 'tug of war' occurs.
Origin of Cultured Cells: Not Where You Think
Study shows cultured cells from decades-old cell line does not originate from the patient it was claimed to derive from.
Worms Point Way Toward Viral Strategies
Rice University wins NIH grant to study how nematodes handle gastrointestinal viruses.
Hope for Zika Treatment Found in Drug Screening
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!